Upper tract urothelial carcinoma (UTUC) is a rare malignancy, representing only 5–10% of urothelial carcinoma. The mainstay of treatment for high-risk patients is radical nephroureterectomy. Given the aggressive behavior of this disease, additional treatments could be required perioperatively in terms of chemotherapy (CHT), either in a neoadjuvant or adjuvant setting. On the other hand, low-risk and selected cases can be managed with kidney-sparing surgery (KSS). The ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) is an ongoing international, multicenter registry of patients undergoing surgery for UTUC. After conducting a literature search in February 2025 using the MEDLINE (via PubMed) and Embase databases, we identified 14 studies based on the ROBUUST data analyses. There are several key topics concerning UTUC that remain under debate and were therefore addressed in these studies, focusing on preoperative evaluation and planning, surgical techniques and intraoperative procedures, additional perioperative treatments, and outcomes. The ROBUUST registry has served as a valuable source for a growing body of investigations focusing on various aspects of UTUC treatment planning, decision-making, and outcomes, providing innovative tools and enabling large-scale, novel analyses.
上尿路尿路上皮癌（UTUC）是一种罕见的恶性肿瘤，仅占尿路上皮癌的5–10%。对于高危患者，根治性肾输尿管切除术是主要的治疗手段。鉴于该疾病的侵袭性行为，围手术期可能需要额外的化疗（CHT）治疗，无论是新辅助还是辅助治疗。另一方面，低风险和经过选择的病例可以通过保留肾脏手术（KSS）进行治疗。上尿路尿路上皮癌机器人手术研究（ROBUUST）是一项正在进行的国际多中心注册研究，收录接受UTUC手术的患者。通过2025年2月在MEDLINE（通过PubMed）和Embase数据库进行文献检索，我们基于ROBUUST数据分析确定了14项研究。关于UTUC的几个关键议题仍存在争议，这些研究主要围绕术前评估与规划、手术技术与术中操作、围手术期附加治疗以及治疗结局展开讨论。ROBUUST注册库已成为日益增多的研究的重要数据来源，这些研究聚焦于UTUC治疗规划、决策制定和结局的各个方面，提供了创新工具，并支持了大规模的新型分析。
肿瘤(癌症)患者之家